Different business models in an ever-challenging funding landscape – the legal view

As the biotech funding environment evolves, particularly in early seed and Series A rounds, companies are adapting their business models. Approaches like early platform deals with pharma partners and “build-to-buy” setups, once seen as less favorable (seen as not to give value away), are making a comeback.

This event, organized with Vischer and Walder Wyss, will focus on the legal aspects of these business models. We’ll cover how to structure these setups, what to watch out for, how to handle termination, and typical timelines.

Join us for insights into the legal considerations that can help guide your business through today’s funding challenges. Comment on our LinkedIn page or submit your questions through this form

This event is powered by Innosuisse.